How should I manage musculoskeletal pain (body aches) caused by Ozempic (semaglutide)?

Management of Musculoskeletal Pain (Body Aches) with Ozempic (Semaglutide)

Body aches associated with Ozempic are not a commonly recognized side effect in FDA labeling or major clinical guidelines, but emerging case reports suggest potential musculoskeletal complications that warrant clinical attention.

Understanding the Problem

The FDA label for Ozempic lists nausea, vomiting, diarrhea, abdominal pain, and constipation as the most common side effects 1, but does not specifically mention generalized body aches or musculoskeletal pain as a recognized adverse effect. However, recent case reports have documented concerning musculoskeletal complications including:

• Rhabdomyolysis with severe muscle pain and cramping, particularly after dose escalation 2
• Allodynia (skin tenderness/hypersensitivity to touch) occurring at the 2.4 mg dose 3
• Neuromuscular junction degradation with declining muscle strength and physical performance in older adults 4
• Immune-mediated necrotizing myopathy with progressive muscle weakness 5

Clinical Assessment Algorithm

Step 1: Characterize the pain pattern

• Onset timing relative to semaglutide initiation or dose escalation
• Severity and location (generalized vs. localized)
• Associated symptoms: muscle weakness, dark urine, skin tenderness, difficulty swallowing

Step 2: Check for serious complications immediately

Obtain urgent laboratory testing if any red flags present:

• Creatine kinase (CK) - to rule out rhabdomyolysis (normal: 20-200 U/L)
• Liver enzymes (AST/ALT)
• Urinalysis for myoglobinuria
• Serum creatinine for kidney function

Red flag symptoms requiring immediate evaluation:

• Bilateral lower extremity pain with dark urine (rhabdomyolysis) 2
• Progressive proximal muscle weakness with dysphagia (necrotizing myopathy) 5
• Severe skin tenderness preventing normal touch (allodynia) 3

Management Strategy

If Serious Complications Identified (CK >1000 U/L or severe weakness):

Immediately discontinue semaglutide and provide supportive care:

• Aggressive IV hydration for rhabdomyolysis
• Nephrology consultation if acute kidney injury develops
• Neurology/rheumatology consultation for suspected myopathy
• Consider immunosuppression (corticosteroids + IVIG) for immune-mediated myopathy 5

If Mild-to-Moderate Body Aches Without Red Flags:

Option 1: Dose reduction approach

• Reduce to previous tolerated dose (e.g., from 2.4 mg to 1.0 mg weekly)
• Monitor for symptom resolution over 2-4 weeks
• Case reports show symptom resolution occurred in 2 of 4 patients after stopping, with one experiencing resolution after 4 months of continuation 3

Option 2: Symptomatic management while continuing therapy

• Topical NSAIDs with menthol gel as first-line for localized musculoskeletal pain 6
• Oral NSAIDs (e.g., ibuprofen 400-600 mg TID) for generalized pain 6
• Avoid opioids including tramadol 6
• Ensure adequate hydration (important given GI side effects that can cause dehydration) 1

Option 3: Discontinuation

• Consider switching to alternative GLP-1 RA (liraglutide) or different medication class
• Guidelines support liraglutide 3.0 mg as alternative with similar efficacy profile 7, 8

Special Considerations

For older adults with diabetes: Be particularly vigilant, as semaglutide may be associated with neuromuscular junction degradation, declining handgrip strength, and elevated biomarkers of neuronal damage (CAF22, NfL) over 6-12 months 4. Monitor muscle strength and physical performance regularly.

Dose escalation timing: The rhabdomyolysis case occurred 6 days after increasing from 1.7 mg to 2.4 mg 2, and allodynia cases all occurred at the 2.4 mg dose 3. Slower titration or avoiding maximum doses may reduce risk.

Paradoxical benefit in osteoarthritis: Emerging research suggests semaglutide may actually improve joint pain and function in knee osteoarthritis through anti-inflammatory and metabolic effects 9, 10, 11, so body aches specifically in weight-bearing joints might improve rather than worsen with continued therapy.

Common Pitfalls to Avoid

• Don't dismiss muscle pain as "normal" without checking CK levels - rhabdomyolysis can develop rapidly after dose escalation
• Don't continue escalating doses if new musculoskeletal symptoms emerge - hold at current dose or reduce
• Don't assume all body aches are drug-related - maintain differential diagnosis including viral illness, fibromyalgia, hypothyroidism
• Don't overlook dehydration - GI side effects (nausea, vomiting, diarrhea) can worsen muscle symptoms 1

Monitoring Protocol

For patients continuing semaglutide with body aches:

• Baseline and follow-up CK at 2 weeks, then monthly for 3 months
• Assess muscle strength and functional status at each visit
• Patient education on warning signs: dark urine, severe weakness, inability to rise from chair
• Document temporal relationship and Naranjo probability score if considering adverse drug reaction

The decision to continue versus discontinue should prioritize patient safety over weight loss goals, particularly given the potential for serious neuromuscular complications in susceptible individuals.